Core Insights - ORIC Pharmaceuticals announced a poster presentation at the ESMO Asia Congress 2025, focusing on data from a Phase 1b trial of enozertinib (ORIC-114) for patients with HER2 exon 20 mutant NSCLC [1][2] Presentation Details - The poster presentation is titled "Enozertinib (ORIC-114), a Highly Selective, Brain Penetrant EGFR and HER2 Inhibitor, in Patients with HER2 Exon 20 Mutant NSCLC: Randomized Dose Optimization" [2] - Presentation number is 981P, scheduled for December 5, 2025, from 5:15 to 6:15 p.m. SGT [2] Conference Call and Webcast - ORIC will host a conference call and webcast on December 6, 2025, at 8:00 p.m. ET, allowing for live Q&A participation [3] - A live webcast and audio archive will be available on ORIC's investor website for 90 days following the presentation [3] Company Overview - ORIC Pharmaceuticals is a clinical stage biopharmaceutical company focused on overcoming resistance in cancer [4] - Key product candidates include ORIC-944 for prostate cancer and enozertinib (ORIC-114) targeting various mutations across multiple cancers [4]